(Q37798157)

23 August 2017

title

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

1 reference

Paul J Clark

1

1 reference

23 August 2017

Alex J Thompson

series ordinal

2

1 reference

23 August 2017

John G McHutchison

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

5 October 2010

1 reference

The American Journal of Gastroenterology

23 August 2017

published in

1 reference

23 August 2017

volume

106

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

38-45

1 reference

How to use an article about genetic association: A: Background concepts

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

How to interpret a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Genome-wide association studies for common diseases and complex traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Evaluating and improving power in whole-genome association studies using fixed marker sets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Common genetic variation and human traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Replicating genotype-phenotype associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Genome-wide association studies for complex traits: consensus, uncertainty and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Assessment of cumulative evidence on genetic associations: interim guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Treatment responses in Asians and Caucasians with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

Population genomics: Linkage disequilibrium holds the key

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.370

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.370

1 reference

release_qdyvlfm2tbdhlf6kw4sdncyllu

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qdyvlfm2tbdhlf6kw4sdncyllu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference